<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126103">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01959074</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-URO-2012-04</org_study_id>
    <secondary_id>SNUH-URO-2012-04-DJ</secondary_id>
    <nct_id>NCT01959074</nct_id>
  </id_info>
  <brief_title>The Effect of Naftopidil for the Double-J Stent Discomfort</brief_title>
  <official_title>The Effect of Naftopidil for the Double-J Stent Discomfort: Multicenter, Randomized, Double-blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is To confirm the efficacy of Naftopidil for reducing discomfort of ureteral
      stent after urinary stone surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Enrollment

             1. patients underwent Double-J ureteral stent indwelling after urological surgery
                during less than 15 days

             2. patients aged more than 20 years

        2. Randomization

             1. naftopidil 75 mg qd or placebo until Double-J stent removal

             2. Standard treatment with pain-killers on demand were also applied.(aceclofenac)

        3. Follow-up to the day of Double-J stent removal (Evaluation should be done at stent
           removal)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ureteral Stent Symptom Questionaire(USSQ) urinary symptom score</measure>
    <time_frame>at the day of DJ stent removal, an expected average of 10 days (range: 5-15 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>DJ stent removal should be done between study day 5 and 15.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>USSQ body pain score</measure>
    <time_frame>at the day of DJ stent removal, an expected average of 10 days (range: 5-15 days)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>USSQ general health score</measure>
    <time_frame>at the day of DJ stent removal, an expected average of 10 days (range: 5-15 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>USSQ work performance score</measure>
    <time_frame>at the day of DJ stent removal, an expected average of 10 days (range: 5-15 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>USSQ sexual matters score</measure>
    <time_frame>at the day of DJ stent removal, an expected average of 10 days (range: 5-15 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score(IPSS), QoL score</measure>
    <time_frame>at the day of DJ stent removal, an expected average of 10 days (range: 5-15 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total analgesics use</measure>
    <time_frame>at the day of DJ stent removal, an expected average of 10 days (range: 5-15 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Disorder of Urinary Stent</condition>
  <arm_group>
    <arm_group_label>Naftopidil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This interventional group will receive analgesics and naftopidil 75mg po qd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control groups with only analgesics</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control groups will receive only analgesics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftopidil</intervention_name>
    <description>Naftopidil 75mg qd + standard treatment (aceclofenac 100mg on demand) vs placebo qd + standard treatment (aceclofenac 100mg on demand)</description>
    <arm_group_label>Naftopidil</arm_group_label>
    <other_name>Flivas(TM) in South Korea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Patients to be undergone double-J stent indwelling

          -  &gt;= 20 years

          -  undergoing unilateral retrograde double J (DJ) stent placement planned for 5-15 days
             indwelling

        Exclusion Criteria:

          -  after percutaneous nephrolithotomy, open or laparoscopic ureterolithotomy presence of
             ureteral stone

          -  renal insufficiency (serum Cr &gt; 1.4)

          -  febrile urinary tract infection (fever &gt; 38.0Â°C, evidence of urinary infection )

          -  pregnancy or breast feeding

          -  solitary kidney

          -  hypersensitivity to Naftopidil

          -  current use of any alpha blocker, calcium channel blocker, corticosteroid moderate or
             sever cardiovascular or cerebrovascular disease

          -  hepatic dysfunction

          -  prior history of pelvic surgery or irradiation

          -  prior history of transurethral resection of bladder tumor or prostate surgery

          -  significant active medical illness which in the opinion of the investigator would
             preclude protocol treatment

          -  genetic disorder such ad galactose intolerance, lapp lactase deficiency,
             glucose-galactose malabsorption
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang Wook Jeong, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chang Wook Jeong, M.D., Ph.D.</last_name>
    <phone>82-10-8933-4353</phone>
    <email>drboss@korea.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jong Jin Oh, M.D.</last_name>
    <phone>82-10-3747-5354</phone>
    <email>bebsuzzang@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Kyunggi</state>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sangchul Lee, M.D., Ph.D.</last_name>
      <phone>82-31-787-7340</phone>
      <email>uromedi@naver.com</email>
    </contact>
    <investigator>
      <last_name>Sangchul Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangwon National University Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sang Wook Lee, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Sang Wook Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hong Zoo Park, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Donguk University Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Min Chul Jo</last_name>
    </contact>
    <investigator>
      <last_name>Min Chul Jo, M.D, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center, Bundang hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jong Jin Oh, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jong Jin Oh, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Woong Na, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Woong Na, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jong Bok Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Boramae Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seong Young Jo, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Seong Young Jo, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyeon Jeong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 29, 2013</lastchanged_date>
  <firstreceived_date>September 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Chang Wook Jeong</investigator_full_name>
    <investigator_title>M.D, Ph.D.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Naftopidil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
